Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified pathogen and it is assumed there is no pre-existing human immunity to the virus. Initial seroconversion, including neutralizing antibodies, has been documented and there is some evidence that immunity to SARS-CoV-2 re-challenge during early convalescence is likely. Continue reading “Case Definition for Coronavirus Disease 2019 (COVID-19)”
A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in China in December 2019. There is limited support for many of its key epidemiologic features, including the incubation period for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for surveillance and control activities. Continue reading “Viral Dynamics of Coronavirus (Covid-19)”
There is currently no vaccine to prevent coronavirus disease 2019 (Covid-19).
The best way to prevent illness is to avoid being exposed to this virus. Continue reading “Prevention of Coronavirus Disease (Covid-19)”
During the initial phase of the Covid-19 outbreak, the diagnosis of the disease was complicated by the diversity in symptoms and imaging findings and in the severity of disease at the time of presentation. Continue reading “Clinical Characteristics of Coronavirus Disease (Covid-19)”
Reported symptoms have included fever in 90% of cases, fatigue and a dry cough in 80%, and shortness of breath in 20%, with respiratory distress in 15%. Chest x-rays have revealed signs in both lungs. Vital signs were generally stable at the time of admission of those hospitalised. Blood tests have commonly shown low white blood cell counts (leucopenia and lymphopenia). Continue reading “Surveillance Case Definitions for Human Infection with Novel Coronavirus (Covid-19)”